Clinical Trials Logo

Filter by:
NCT ID: NCT05180994 Recruiting - Clinical trials for Glaucoma Following Surgery

Topical Infliximab in Eyes With Penetrating Keratoplasty

Start date: May 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.

NCT ID: NCT05180968 Completed - Clinical trials for End Stage Renal Disease

DIalysis Symptom COntrol-Pruritus Outcome Trial

DISCO-POT
Start date: August 2, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to test whether or not a medication called nabilone, which is a synthetic (non-natural) medication derived from cannabis, compared to placebo improves symptoms of itch in hemodialysis as measured by visual analog scales.

NCT ID: NCT05180656 Completed - Breast Cancer Clinical Trials

Feasibility of a Remotely-Delivered Yoga Intervention on Cognitive Function in Breast Cancer Survivors

Start date: December 13, 2021
Phase: N/A
Study type: Interventional

The purpose of this pilot study is to assess the feasibility of a remotely-delivered yoga intervention for breast cancer survivors.

NCT ID: NCT05180240 Recruiting - Acute Myocarditis Clinical Trials

Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis

ARCHER
Start date: June 22, 2022
Phase: Phase 2
Study type: Interventional

Multi-center, double-blind, placebo-controlled, parallel group design. Patients with myocarditis will be screened and, if eligible, randomized within 10 days of the diagnostic CMR to CardiolRx or placebo. CardiolRx is pharmaceutically produced Cannabidiol and is free of tetrahydrocannabinol (THC<5 ppm). The treatment period is 12 weeks; a last follow-up visit is scheduled one week after the last treatment, 13 weeks after randomization. Study assessments include Cardiac Magnetic Resonance imaging (CMR), ECG monitoring, the Kansas City Cardiomyopathy Questionnaire (KCCQ), the Columbia-Suicide Severity Rating Scale (C-SSRS) as well as physical exams and laboratory tests. The primary and secondary outcome parameters are measured by CMR. Additional outcomes include clinical endpoints and changes in inflammatory and biomarkers.

NCT ID: NCT05180097 Recruiting - Hodgkin Lymphoma Clinical Trials

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Start date: November 1, 2022
Phase: Phase 2
Study type: Interventional

This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.

NCT ID: NCT05179473 Recruiting - Stroke, Acute Clinical Trials

Prognosis and Diagnosis of Spasticity in Acute-post Stroke Patients

Start date: June 17, 2021
Phase:
Study type: Observational

Spasticity, or greater muscle resistance, is a major disabling condition following stroke. Recovery of lost motor function in patients with stroke may be affected by spasticity, which most commonly develops in elbow and ankle muscles. However, despite its clinical relevance, the natural development of spasticity over the first 3 months after stroke is not clearly understood. Indeed, common clinical measures of spasticity such as the Modified Ashworth Scale (MAS) do not take into account the neurophysiological origin of spasticity and lack reliability and objectivity. The objective of this study is to examine the natural history of the development of spasticity among patients with stroke over the first 3 months using a new neurophysiological measure (TSRT, the tonic stretch reflex threshold angle) and its velocity sensitivity (mu) in comparison to MAS and other common clinical tests. In addition, detailed brain imaging will be used to understand the relationship between damage to brain regions relevant to the development of spasticity and TSRT/mu values. It is hypothesized that 1) TSRT/mu will indicate the presence of spasticity earlier than MAS/clinical tests; 2) TSRT/mu measures will be more closely related to motor impairments and activity limitations than MAS; 3) the lesion severity (identified by imaging) will be related to the change in TSRT/mu values. Outcomes will be measured in a pilot cohort of 12 patients hospitalized for first-ever stroke. Measurements will be taken at the bedside within the 1st week of the patient's admission and will be done once per week for 12 weeks with a follow-up at week 16. Brain Imaging will be done around the 6th week post-stroke.

NCT ID: NCT05179148 Active, not recruiting - Clinical trials for Motivational Interviewing

MI for Physical Activity Among Older Adults

Start date: March 23, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the feasibility of VIrtual Motivational INTerviewing (VIMINT) to promote physical activity levels among older adults; post-intervention and at two-month follow-up.

NCT ID: NCT05179057 Terminated - Clinical trials for Adenovirus Infection

Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

Start date: April 26, 2022
Phase: Phase 3
Study type: Interventional

This study will assess the safety and efficacy of Posoleucel for the treatment of adenovirus (AdV) infection in pediatric and adult allo-HCT recipients receiving standard of care (SoC).

NCT ID: NCT05179031 Completed - Glycemic Response Clinical Trials

Assessment of the Glycemic Responses to Nutritional Products

GLIN#1
Start date: January 4, 2022
Phase: N/A
Study type: Interventional

This study assesses the glycemic responses to nutritional products. During a study visit fasted subjects will consume one serving of the reference product or the test product. Capillary blood samples will be taken at baseline and at several time-points over a 2-hr period. Several nutritional products will be tested over time.

NCT ID: NCT05178862 Suspended - Candidemia Clinical Trials

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

MARIO
Start date: August 3, 2022
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin followed by oral fluconazole.